In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Amphastar Pharmaceuticals trades significantly below its high-confidence PERT fair value of $56.60, indicating potential undervaluation supported by diverse valuation methods, including a strong DCF mid-point of $88.31. Financial health shows good liquidity and profitability but modest growth, aligning with stable fundamentals. Monte Carlo analysis reveals high upside potential and negligible downside risk relative to current price, though with notable volatility.